Search - tctmd.com

Displaying 321 - 340 of 526

Sort: Relevancy | Date

News Daily News

La Protección Embólica Proximal podría ser la Fórmula Preferida en la Implantación de Stents Carotídeos

August 07, 2014

News Daily News

Long-term Mortality Worse for Black vs White NSTEMI Patients, Linked with Treatment Discrepancies

July 17, 2014

News Daily News

HEAT-PPCI发布：关于直接PCI中肝磷脂较比伐卢定有优势的差异性发现仍然难以理解

Yael L. Maxwell

July 17, 2014

News Daily News

HEAT-PPCI Published: Discrepant Finding of Heparin’s Superiority over Bivalirudin in Primary PCI Still Puzzles

Yael L. Maxwell

July 17, 2014

News Daily News

HEAT-PPCI Publicado: El Discrepante Hallazgo de la Superioridad de la Heparina sobre la Bivalirudina en PCI Primarias Sigue Confundiendo

Yael L. Maxwell

July 17, 2014

News Industry News

Bristol-Myers Squibb and Pfizer Announce Enrollment of First Patient in Phase IV EMANATE Trial to Assess Effectiveness and Safety of Eliquis® (apixaban) in Patients with NVAF Undergoing Cardioversion

July 17, 2014

News Daily News

La Mortalidad a Largo Plazo es Peor en Pacientes NSTEMI de Raza Negra que en Pacientes de Raza Blanca con Discrepancias en el Tratamiento

July 17, 2014

News Daily News

ACUITY分项研究： Syntax评分与NSTE-ACS患者的支架内血栓形成有关联

L.A. McKeown

July 09, 2014

News Daily News

ACUITY Substudy: Syntax Score Correlates with Stent Thrombosis in NSTE-ACS Patients

L.A. McKeown

July 09, 2014

News Daily News

Subestudio ACUITY: La Puntuación obtenida en la Escala Syntax Guarda Relación con la Trombosis del Stent en Pacientes SCASEST

L.A. McKeown

July 09, 2014

News Industry News

The Medicines Company Receives Market Authorization Renewal for Angiox® (Bivalirudin) from the European Medicines Agency and the European Commission

July 07, 2014

News Daily News

Strategy of Potent Anticoagulation with Rapid Post-PCI Reversal Appears Safe, Effective

L.A. McKeown

July 03, 2014

News Daily News

Una Estrategia de Anticoagulación Potente con Reversión Rápida Post-PCI parece Segura y Efectiva

L.A. McKeown

July 03, 2014

News Daily News

Prasugrel Efficacy in STEMI Largely Unaffected by PCI Timing

Yael L. Maxwell

June 17, 2014

News Industry News

Data on Angiox (Bivalirudin Injection) in Heart Attack Patients Presented at EuroPCR and Published in European Heart Journal

May 22, 2014

News Conference News EuroPCR 2014

EUROMAX Subanalysis: Bivalirudin Bests Heparin Regardless of GPI Use in STEMI

Yael L. Maxwell

May 21, 2014

News Daily News

BRAVE 4: Prasugrel Plus Bivalirudin Fails to Mitigate Stent Thrombosis in STEMI Patients

May 14, 2014

News Daily News

Hospital-Acquired Thrombocytopenia Increases Risk of Hospital Bleeding, 1-Year Mortality

May 05, 2014

News Daily News

Bivalirudin Safer Than Heparin Alone in ‘Real-World’ PCI Patients Without STEMI

Yael L. Maxwell

May 01, 2014

News Daily News

STEMI Patients with Large Thrombus Benefit from Low-dose Thrombolysis

Yael L. Maxwell

April 10, 2014

Advertisement

La Protección Embólica Proximal podría ser la Fórmula Preferida en la Implantación de Stents Carotídeos

Long-term Mortality Worse for Black vs White NSTEMI Patients, Linked with Treatment Discrepancies

HEAT-PPCI发布：关于直接PCI中肝磷脂较比伐卢定有优势的差异性发现仍然难以理解

HEAT-PPCI Published: Discrepant Finding of Heparin’s Superiority over Bivalirudin in Primary PCI Still Puzzles

HEAT-PPCI Publicado: El Discrepante Hallazgo de la Superioridad de la Heparina sobre la Bivalirudina en PCI Primarias Sigue Confundiendo

Bristol-Myers Squibb and Pfizer Announce Enrollment of First Patient in Phase IV EMANATE Trial to Assess Effectiveness and Safety of Eliquis® (apixaban) in Patients with NVAF Undergoing Cardioversion

La Mortalidad a Largo Plazo es Peor en Pacientes NSTEMI de Raza Negra que en Pacientes de Raza Blanca con Discrepancias en el Tratamiento

ACUITY分项研究： Syntax评分与NSTE-ACS患者的支架内血栓形成有关联

ACUITY Substudy: Syntax Score Correlates with Stent Thrombosis in NSTE-ACS Patients

Subestudio ACUITY: La Puntuación obtenida en la Escala Syntax Guarda Relación con la Trombosis del Stent en Pacientes SCASEST

The Medicines Company Receives Market Authorization Renewal for Angiox® (Bivalirudin) from the European Medicines Agency and the European Commission

Strategy of Potent Anticoagulation with Rapid Post-PCI Reversal Appears Safe, Effective

Una Estrategia de Anticoagulación Potente con Reversión Rápida Post-PCI parece Segura y Efectiva

Prasugrel Efficacy in STEMI Largely Unaffected by PCI Timing

Data on Angiox (Bivalirudin Injection) in Heart Attack Patients Presented at EuroPCR and Published in European Heart Journal

EUROMAX Subanalysis: Bivalirudin Bests Heparin Regardless of GPI Use in STEMI

BRAVE 4: Prasugrel Plus Bivalirudin Fails to Mitigate Stent Thrombosis in STEMI Patients

Hospital-Acquired Thrombocytopenia Increases Risk of Hospital Bleeding, 1-Year Mortality

Bivalirudin Safer Than Heparin Alone in ‘Real-World’ PCI Patients Without STEMI

STEMI Patients with Large Thrombus Benefit from Low-dose Thrombolysis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content